Pharmacological management of panic disorder

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 A, 2008, Pages 93-106

  Marchesi, Carlo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Panic disorder; Pharmacological treatment; Treatment guidelines

Indexed keywords

ALPRAZOLAM; ANTIPANIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENELZINE; PINDOLOL; PLACEBO; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; AGORAPHOBIA; ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY; ANXIETY DISORDER; BEHAVIOR THERAPY; BREAST FEEDING; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIET RESTRICTION; DISEASE SEVERITY; DROWSINESS; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEADACHE; HUMAN; INFANTILE HYPOTONIA; INSOMNIA; LOW DRUG DOSE; MENTAL INSTABILITY; MOTOR DYSFUNCTION; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PANIC; PATHOGENESIS; PATIENT EDUCATION; PERSONALITY DISORDER; PREGNANCY; PSYCHIATRIC TREATMENT; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUBSTANCE ABUSE; SWEATING; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 41549120592     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1557     Document Type: Review

References (104)

1. American Academy of Pediatrics. 2000. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics, 105:880-7.
2. American College of Obstetrician and Gynecologists. 2006. Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol, 108:1601-3.
3. Ampollini P, Marchesi C, Signifiredi R, et al. 1999. Temperament and personality features in patients with major depression, panic disorder and mixed conditions. J Affect Disord, 52:203-7.
4. [APA] American Psychiatric Association. 1998. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry, 155(Suppl 5):1-34.
5. [APA] American Psychiatric Association. 2000. Diagnostic and stastical manual of mental disorders. Fourth edition, text revised. Washington, DC: American Psychiatric Association
6. Bakker A, van Balkom AJ, Spinhoven P, et al. 2002. SSRIs vs. TCAs in the treatment of panic disorder: a meta-anlsysis. Acta Psychiatr Scand, 106:163-7.
7. Baldwin DS, Anderson IM, Nutt DJ, et al. 2005. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association of Psychopharmacology. J Psychopharmacol, 19:567-96.
8. Ballenger JC. 1997. Panic disorder in the medical setting. J Clin Psychiatry, 58(Suppl 2):13-17.
9. Ballenger JC. 1999. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry, 60(Suppl 22):29-34.
10. Ballenger JC. 2001. Treatment of anxiety disorders to remission. J Clin Psychiatry, 62(Suppl 12):5-9.
11. Ballenger JC, Davidson JRT, Lecrubier Y, et al. 1998. Consensus statement on panic disorder from the international consensus group on depression and anxiety. J Clin Psychiatry, 59(Suppl 8):47-54.
12. Bandelow B, Sojka F, Broocks A, et al. 2006. Panic disorder during pregnancy and postpartum period. Eur Psychiatry, 21:495-500.
13. Bandelow B, Zohar J, Hollahder E, et al. 2002. World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry, 3:171-99.
14. Barbey JT, Roose SP. 1998. SSRI safety in overdose. J Clin Psychiatry, 59(Suppl 15):42-8.
15. Barlow DH, Gorman JM, Shear MK, et al. 2000. Cognitive-behavioural therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA, 283:2529-36.
16. Berard A, Ramos E, Rey E, et al. 2006. First trimester exposure to paroxetina and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol, 80:18-27.
17. Berle JO, Steen VM, Aamo TO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms and cytichrome p450 genotypes. J Clin Psychiatry, 65:1228-34.
18. Bradwejn J, Ahokas A, Stein DJ, et al. 2005. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry, 187:352-9.
19. Bruce SJ, Vasile RG, Goisman RM, et al. 2003. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry, 160:143 2-8.
20. [CPA] Canadian Psychiatric Association. 2006. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry, 51 (8 suppl 2): 9S-91S.
21. Chambers CD, Hernandez-Diaz S, Van Mater LJ, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 354:579-87.
22. Cowley DS, Ha EH, Roy-Byrne PP, et al. 1997. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry, 58:555-61.
23. Davidson JRT. 1998. The long-term treatment of panic disorder. J Clin Psychiatry, 59(Suppl 8):17-21.
24. den Boer JA. 1998. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry, 5 9(Suppl 8):30-6.
25. Doerfler LA, Connor DF, Volungis AM, et al. 2006. Panic disorder in clinically referred children and adolescents. Child Psychiatry Hum Dev, in press.
26. Doyle A, Pollack MH. 2003. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry, (Suppl 15):40-5.
27. Doyle A, Pollack MH. 2004. Long-term management of panic disorder. J Clin Psychiatry, 65(Suppl 5):24-8.
28. Dreessen L, Arntz A. 1998. The impact of personality disorders on treatment outcome of anxiety disorders: best-evidence synthesis. Behav Res Ther, 36:483-504.
29. Eaton WW, Anthony JC, Romanoski A, et al. 1998. Onset and recovery from panic panic disorders in the Baltimore Epiderniologic Catchment Area follow-up. Br J Psychiatry, 173:501-7.
30. Eberhard-Gran M, Esklid A, Opjordsmoen S. 2005. Treating mood disorders during pregnancy: safety considerations. Drug Saf, 28:695-706.
31. Eberhard-Gran M, Esklid A, Opjordsmoen S. 2006. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs, 20:187-98.
32. Goddard AW, Brouette T, Almai A, et al. 2001. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry, 58:681-6.
33. Goisman RM, Warshaw MG, Peterson LG, et al. 1994. Panic, agoraphobia, and panic disorder with agoraphobia. Data from a multicenter anxiety disorders study. J Nerv Ment Dis, 182:72-9.
34. Goodwin RD, Gotlib IH. 2004. Panic attacks and psychopathology among youth. Acta Psychiatr Scand, 109:216-21.
35. Goodwin RD, Roy-Byrne P. 2006. Panic and suicidal ideation and suicide attempts: results from the National Comorbidity Survey. Depress Anxiety, 23:124-32.
36. Grant BF, Hasin DS, Stinson FS, et al. 2005. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. J Psychiatr Res, 39:1-9.
37. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. 1998. Drug interactions with newer antidepressant: role of human cytochromes P450. J Clin Psychiatry, 59(Suppl 15):19-27.
38. Heldt E, Manfro GG, Kipper L, et al. 2003. Treating medication-resistant panic disorder: predictors of cognitive-behaviour therapy in a Brazilian public hospital. Psychother Psychosom, 72:43-8.
39. Heldt E, Manfro GG, Kipper L, et al. 2006. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behaviour therapy: outcome and predictors of remission. Behav Res Ther, 44:657-65.
40. Hischmann S, Dannon PM, Iancu I, et al. 2000. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo controlled trial. J Clin Psychopharmacol, 20:556-9.
41. Hollifield M, Thompson PM, Ruiz JE, et al. 2005. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety, 21:33-40.
42. Iqbal MM, Sobhan T, Ryals T, 2002. Effects of commonly used benzodiazepines on the fetus, the neonate, and nursing infant. Psychiatr Serv, 53:39-49.
43. Kallen B, Olausson PO. 2006. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol, 21:221-2.
44. Katerndahl DA, Realini JP. 1995. Where do panic sufferers seek care? J Fam Pract, 40:237-43.
45. Katschnig H, Amering M. 1998. The long-term course of panic disorder and its predictors. J Clin Psychopharmacol, 18(Suppl 2):6-11.
46. Kessler RC, Berglund P, Demler O, et al. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62: 593-602.
47. Kessler RC, Chiu WT, Demler O, et al. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:617-27.
48. Kessler RC, Stang P, Wittchen H, et al. 1998. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry, 55:801-08.
49. Khan A, Kolts RL, Rapaport MH, et al. 2005. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med, 35:743-9.
50. Klein DF. 1964. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 17:397-408.
51. Kroenke K. 2003. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res, 12:34-43.
52. Lecrubier Y. 1998. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry, 59(Suppl 8):11-14.
53. Malm H, Klaukka T, Neuvonen PJ. 2005. Risks associated with selective scrotonin reuptake inhibitors in pregnancy. Obstet Gynecol, 106:1289-96.
54. Marchesi C, Brusamonti E, Giannini A, et al. 2001. The use of an emergency ward by patients with depressive or anxiety disorders: a one year follow-up study. Int J Psychiatr Med, 31:265-75.
55. Marchesi C, Brusamonti E, Borghi C, et al. 2004. Anxiety and depressive disorders in an emergency department ward of a general hospital: a control study. Emerg Med J, 21:175-9.
56. Marchesi C, Cantoni A, Fontò S, et al. 2005. The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study. J Affect Disord, 89:189-94.
57. Marchesi C, Cantoni A, Fontò S, et al. 2006a. Predictors of symptom resolution in Panic Disorder after one year of pharmacological treatment: a naturalistic study. Pharmacopsychiatry, 39:60-5.
58. Marchesi C, Cantoni A, Fontò S, et al. 2006b. The effect of temperament and character on response to Selective Serotonin Reuptake Inhibitors in Panic Disorder. Acta Psychiatr Scand, 114: 203-10.
59. Marchesi C, De Panfilis C, Cantoni A, et al. 2006. Personality Disorders and response to medication treatment in Panic Disorder: a one year naturalistic study. Prog Neuro-Psychopharmacol Biol Psychiatry, 30:1240-45.
60. Maron E, Shlik J. 2006. Serotoni function in panic disorder: important, but why? Neuropsychopharmacology, 31:1-11.
61. Masi G, Favilla L, Mucci M, et al. 2000. Panic disorder in clinically referred children and adolescents. Child Psychiatry Hum Dev, 31:139-51.
62. Masi G, Pari C, Millepiedi S. 2006. Pharmacological treatment options for panic disorder in children and adolescents. Expert Opin Pharmacother, 7:545-54.
63. Massion AO, Dyck IR, Shea MT, et al. 2002. Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder. Arch Gen Psychiatry, 59:434-40.
64. Mathew SJ, Caplan JD, Gorman JM. 2001. Management of treatment-refractory panic disorder. Psychopharmacol Bul, 35:97-110.
65. Mavissakahan MR, Perel JM. 2002. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol, 22:294-9.
66. Mitte K. 2005. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord, 88:27-45.
67. Moses-Kolko EL, Bogen D, Perel J, et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA, 293:2372-83.
68. Murphy TK, Bengston MA, Y Tan J, et al. 2000. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int Clin Psychopharmacology, 15(Suppl 2):s47-s63.
69. [NICE] National Institute for Clinical Excellence. 2004. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guideline 22: December 2004. National Collaborating Centre for Primary Care. Available on web site: www.nice.org.uk.
70. Neumeister A, Daher RJ, Charney DS. 2005. Anxiety disorders: noradrenergic neurotrasmission. Handb Exp Pharmacol, 169:205-23.
71. Ninan PT, Dunlop BW 2005. Neurobiology and etiology of panic disorder. J Clin Psychiatry, 66(Suppl 14):3-7.
72. Nulman I, Rovet J, Stewart DE, et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry, 159:1889-95.
73. Ongur D, Farabaugh A, Iosifescu DV, et al. 2005. Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset. Psychother Psychosom, 74:173-8.
74. Otto MW, Tuby KS, Gould RA, et al. 2001. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry, 158:1989-92.
75. Ozkan M., Altindag A, Toni A, et al. 2005. Comorbid personality disorders in subject with panic disorder: Do personality disorders increase clinical severity? Compr Psychiatry, 46:20-6.
76. Pollack MH. 2005. The pharmacotherapy of panic disorder. J Clin Psychiatry, 66(Suppl 4):23-7.
77. Pollack MH, Allgulander MD, Bandelow B, et al. 2003. WCA Recommendations for the Long-Term Treatment of Panic Disorder. CNS Spectr, 8(suppl 1): 17-30.
78. Pollack MH, Simon NM, Worthington JJ, et al. 2003. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol, 17:276-82.
79. [RANZCP] Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia. 2003. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry, 37:641-56.
80. Riederer P, Lachenmayer L, Laux G. 2004. Clinical application of MAO-inhibitors. Curr Med Chem, 11:2033-43.
81. Roose SP, Miyazaki M. 2005. Pharmacologic treatment of depression in patients with heart disease. Psychosom Med, 67(Suppl 1):s54-7.
82. Rosenbaum JF, Pollack MH, Pollock RA. 1996. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry, 57(Suppl 10):44-8.
83. Ross LE, McLean LM. 2006. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry, 67:1285-98.
84. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet, 365:482-7.
85. Sareen J, Cox BJ, Afifi TO, et al. 2005. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population- based study of adults. Arch Gen Psychiatry, 62:1249-57.
86. Schweizer E, Rickels K. 1998. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiat Scand, 98(Suppl 393):95-101.
87. Scott EL, Pollack MH, Otto MW, et al. 1999. Clinician Response to treatment Refractory Panic Disorder. A Survey of Psychiatrists, J Nerv Dis, 187:755-7.
88. Sepede G, De Berardis D, Gambi F, et al. 2006. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed dose, open-label trial. J Clin Psychopharmacol, 26:45-9.
89. Silverman WK, Ollendick TH. 2005. Evidence-Based Assessment of Anxiety and Its Disorders in Children and Adolescents. J Clin Child Adolesc Psychol, 34:380-411.
90. Simon NM, Fischmann D. 2005. The implications of medical and psychiatric comorbidity with panic disorder. J Clin Psychiatry, 4:8-15.
91. Simon NM, Hoge EA, Fischmann D, et al. 2006. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry, 67:381-5.
92. Slaap BR, den Boer JA. 2001. The prediction of nonresponse to pharmacotherapy in panic disoder: a review. Depress Anxiety, 14:112-22.
93. Susman J, Klee B. 2005. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry, 7:5-11.
94. Taylor C, King R, Margraf J, et al. 1989. Use of medication and in vivo exposure in volunteers for panic disorder research. Am J Psychiatry, 146:1423-6.
95. Vickers K, Mc Nally RJ. 2004. Panic disorder and suicide attempt in the National Comorbidity Survey. Depress Anxiety, 113:582-91.
96. Warner CH, Bobo W, Warner C, et al. 2006. Antidepressant discontinuation syndrome. Am Fam Physician, 74:449-56.
97. Weissman MM, Bland RC, Canino GJ, et al. 1997. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry, 54:305-9.
98. Weissman AM, Levy BT, Hartz AJ, et al. 2004. Pooled analysis of antidepressant level in lactating mothers, breast milk, and nursing infants. Am J Psychiatry, 161:1066-78.
99. Wogelius P, Norgaard M, Muff Munk E, et al. 2005. Maternal use of selective serotonin reup-take inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiol Drug Saf, 14:S72.
100. Yonkers KA, Ellison JM, Shera DM, et al. 1996. Description of antipanic therapy in a prospective longitudinal study. J Clin Psychopharmacol, 16:223-32.
101. Zajeca J, Tracy KA, Mitchell S. 1997. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry, 58:291-7.
102. Zamorski MA, Albucher RC. 2002. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. Am Fam Physician, 66:1477-84.
103. Zimmermann P, Wittchen HU, Hoffer M, et al. 2003. Primary anxiety disorders and the development of subsequent alcohol use disorder: a 4-year community study of adolescents and young adults. Psychol Med, 33:1211-22.
104. Zwanzger P, Rupprecht R. 2005. Selective GABAergic tretament for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci, 30:167-75.